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Abstract
Background: Patients with colorectal cancer (CRC) often present with associated anaemia which is usually present
at the time of diagnosis and is aggravated during the postoperative period due to blood loss during the surgery
process. Several guidelines advocate for the treatment of postoperative anaemia in these patients in order to
prevent complications and allogeneic blood transfusions. However, there are no publications to shed light on the
effectiveness of intravenous iron (IVI) administration after CRC surgery and the optimal dose and regimen. We have
started a clinical trial with the objective of comparing the effectiveness of 1000 mg of ferric carboxymaltose with
fractionated iron sucrose 200 g/48 h for the treatment of postoperative anaemia, by measuring the change of
haemoglobin (Hb) levels from postoperative day (POD) 1 to POD 30.
Methods: We designed an open label randomised controlled trial to compare two postoperative IVI treatment
regimens. Patients aged > 18 years undergoing CRC surgery, with Hb < 11 g/dL on POD 1 are randomly assigned to
receive either 1000 mg of ferric carboxymaltose (single dose) or 200 g/48 h of iron sucrose. The main study
endpoint will be the change from POD 1 to POD 30 in Hb levels and the key secondary endpoint the percentage
of patients with Hb levels ≥ 13 g/dL at POD 30. Other secondary endpoints include: changes in iron metabolism
parameters (Fe, ferritin, transferrin, % saturated trasferrin) at POD 30; total doses of iron received; number of
postoperative transfusions; compliance with oral iron treatment; number of medical and surgical complications;
adverse reactions reported by the patient; use of health resources after surgery; and changes in quality of life (QoL).
It has been estimated that a sample of 48 patients per group will allow detecting a difference of 0.75 g/dL in Hb in
the change in Hb levels from POD 1 to POD 30.
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Discussion: The results of this study will confirm if the single dose of 1000 mg ferric carboxymaltose should be
preferred in front of the fractionated doses and in which type of patients this regimen should be used preferably.
Trial registration: European Union Clinical Trials Register, EudraCT 2015-001005-13. Registered on 6 January 2015.
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Background
Patients with colorectal cancer (CRC) often present with
associated anaemia which can be attributed mainly to iron
deficiency due to blood loss and to the inflammation in-
herent to neoplastic processes [1]. Anaemia is usually
present at the time of diagnosis and is aggravated during
the postoperative period due to blood loss during the sur-
gery process. On the other hand, it has been well estab-
lished that preoperative anaemia increases the risk of
allogeneic blood transfusions during the perioperative
period and that transfusions are associated with an in-
crease in postoperative infections, a higher rate of tumour
recurrences and an increase in five-year mortality [1–3].
This is why alternative strategies to optimise patients with
preoperative anaemia have been implemented to avoid
transfusions. Intravenous iron (IVI) has been shown as an
efficacious alternative to transfusion [4–7] and is now
recognised as more effective than the oral route in this
setting. The main reasons why oral iron has been super-
seded by IVI are malabsorption due to the inflammation
associated to the neoplastic process and the poor compli-
ance due to gastric intolerance [8–10].
The optimisation of CRC cancer patients with anaemia
before undergoing surgery was well established in our
centre a decade ago, after a multidisciplinary team imple-
mented a diagnostic track for this type of patients [11].
According to the diagnostic track, all patients presenting
with anaemia at the time of diagnosis should be treated
before surgery with IVI. An expert consensus of different
Spanish scientific societies addresses the management of
anaemia in surgical procedures with medium-high bleed-
ing, such as CRC surgery, and advises that it would be de-
sirable to reach haemoglobin (Hb) levels > 13 g/dL before
surgery in order to minimise the risk of transfusion and
quickly correct the anaemia [10, 12]. However, although
this document also recommends treatment of postopera-
tive anaemia with IVI with the aim of minimising transfu-
sions and complications, there is no robust evidence to
endorse this recommendation.
Titos et al. describe a retrospective study [13] where
treatment with IVI after CRC surgery did not affect the
needs of transfusion nor did it significantly increase Hb
levels. However, it has to be taken into account that the
sample size was small and that patients were only stud-
ied up to the moment they were discharged; thus, doses
received could have been insufficient to induce a signifi-
cant increase in Hb levels.
Currently, the trend in CRC surgery is to initiate food
intake and mobilisation as soon as possible to achieve a
prompt functional recovery of the patient and eventually
shorten hospital stay. In this situation, the treatment of
postoperative anaemia in patients with CRC should be
done early and preferably by IV route, as the patient is
discharged very soon after surgery.
In our hospital, there is an established protocol for the
treatment of postoperative anaemia when it is detected in
these patients, aiming at the normalization of Hb levels.
This protocol establishes that all patients intervened for
CRC, independent of the Hb levels and iron status, must
receive during the early postoperative period 200mg of
IVI to substitute the intraoperative loss of blood. On post-
operative day (POD) 1, patients must have blood tests
with a haemogram. If Hb is < 11 g/dL patients will receive
one dose of 1000mg of ferric carboxymaltose. If Hb is be-
tween 11 and 13 g/dL, patients receive 200mg/48 h of
iron sucrose during hospital stay until iron deficit is solved
(calculated according to Ganzoni Formula) and after hos-
pital discharge, they will be prescribed oral iron in case
the target doses have not been completed. To implement
this protocol, two formulations are available at our institu-
tion: ferric carboxymaltose 500mg strength and iron su-
crose 100mg strength.
Despite the advantages of the single 1000-mg doses
of ferric carboxymaltose administration, that would
guarantee that patients receive the iron load needed
before hospital discharge. In a recent retrospective
study, we observed an underuse of the 1000-mg sin-
gle dose even in patients with low Hb levels [14]. On
the one hand, the difference in cost compared to
fractionated formulations of iron sucrose may account
for this. However, the lack of acceptance of such pro-
tocols may also be related to the limited evidence
perceived by surgeons of the benefit of the 1000-mg
doses over the fractionated doses. In fact, there is a
lack of information of which is the clinical impact of
the two different approaches. Thus, we have consid-
ered that comparing both schemes would give an an-
swer to a relevant clinical question that may impact
clinical practice in the future. Our hypothesis is that
treatments with a single dose of ferric carboxymaltose
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in patients who present with Hb levels < 11 g/dL at
POD 1 will be more effective in achieving normal Hb
levels at POD 30.
Participants and methods
Study design and interventions
This is a single-centre, open-label randomised controlled
trial to compare the effectiveness of two different IVI regi-
mens to treat postoperative anaemia in patients undergo-
ing CRC surgery. During the visit before surgery with the
anaesthesiologist, patients meeting the eligibility criteria
will be informed and those willing to participate will sign
the informed consent form. On POD 1, Hb levels will be
determined and those patients presenting with levels < 11
g/dL will be randomly assigned to one of the following
study treatments: (1) single dose of 1000mg of ferric car-
boxymaltose (Ferinject®, Vifor, France) intravenously in a
15-min infusion; or (2) repeated doses of 200mg of iron
sucrose (different brand names) every 48 h from POD1 up
to hospital discharge or up to the total dose equivalent to
iron deficit calculated according to the Ganzoni formula,
whichever occurs first. Patients who are discharged before
achieving the calculated doses will be prescribed oral iron
up to POD 30. Patients with Hb levels ≥ 11 g/dL on POD
1 will not be included in the study and will follow the
treatment according to hospital protocols. After discharge,
patients will be followed up to POD 30 (Fig. 1).
Study population
Patients aged > 18 years undergoing programmed CRC
surgery, with Hb levels < 11 g/dL on POD 1 and who
have signed the informed consent form (ICF) are in-
cluded in the study. Patients who present with Hb levels
≥ 11 g/dL on POD 1, with anaesthetic risk ASA 4, with
Claviens classification of surgical complications grade 4,
pregnant or lactating women, and patients with previous
known intolerance/adverse reactions or with contraindi-
cations to IVI are excluded.
Randomisation
A computer-generated block randomisation (block size 8)
has been created with WinPepi etcetera module version
3.26. Randomisation has been stratified by Hb level on
day 1 (Hb < 10 g/dL or Hb ≥ 10 g/dL). Sealed envelopes
have been created for each individual patient. Pre-
screened patients are randomly assigned to one of the two
study treatments on POD 1 and after knowing the results
of the blood tests for Hb levels.
Study procedures
During the preoperative anaesthesiology visit, patients
meeting eligibility criteria will be informed and those will-
ing to participate in the study will sign the ICF. During
this visit, and after signing the ICF, patients will complete
a quality-of-life questionnaire (QL-C30). On POD 1, and
after checking eligibility (Hb levels < 11 g/dL), treatment
will be randomly assigned to one of the two treatment
arms. After hospital discharge, patients will come for a
visit on POD 30 when blood tests assessing iron metabol-
ism and Hb will be performed and patients will be asked
to complete the QL-C30 questionnaire. Any additional
blood tests assessing Hb levels and iron metabolism
performed from patient diagnosis to end of trial (i.e.
at diagnosis, immediately before surgery and on POD
4 or hospital discharge) will be recorded. When pa-
tients are hospitalised, regular checks for adverse
events or any complication are performed. Iron treat-
ment will be discontinued in patients admitted in the
intensive care unit on POD 1 due to organic fail or
presenting Claviens grade 4 complications. Whenever
possible, these patients will be followed up to POD
30 (Fig. 2).
Study endpoints
The main study endpoint will be the change in Hb levels
from POD 1 to POD 30. The percentage of patients with
Hb levels ≥ 13 g/dL at POD 30 will be considered as a
key secondary endpoint. Other secondary endpoints
Fig. 1 Study design. Ganzoni Formula: Total iron dose (mg iron) = body weight (kg) × (target – actual Hb) (g/dL) × 2.4 + iron for iron stores (mg iron)*.
*Iron stores: body weight < 35 kg = 15mg/kg body weight; body weight > 35 kg = 500mg
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include: changes in iron metabolism parameters (Fe,
ferritin, transferrin, % saturated trasferrin) at POD 30;
total doses of iron received up to POD 30; number of
postoperative transfusions; percentage of patients not
compliant with oral iron treatment; number of med-
ical and surgical complications; adverse reactions
reported by the patient; and use of health resources
after surgery: number of admissions, length of
hospital stay; changes in quality of life (QoL). Poten-
tial adverse reactions of IVI are headache, dizziness,
nausea, abdominal pain, constipation, diarrhoea,
exanthema, hypophosphatemia and increases in ala-
nine-aminotransferase. Hypersensitivity and injection
site reactions are rare. Oral iron treatment is associ-
ated with gastric intolerance and constipation.
Data collection and management
Study data will be collected in paper case report
forms (CRF) designed for the study. Risk adjusted
monitoring will be performed by personnel independ-
ent from the investigator team, consisting on check-
ing all informed consent forms and completeness of
all CRFs and source data verification for a random
sample of patients. Data will be entered in the study
database by members of the study team. Patients will
be identified by a numerical code and no personal in-




Our hypothesis is that the difference in change in Hb
levels (primary endpoint) between the two studied regi-
mens will be 0.75 g/dL. With a two-sided risk of 5% and
a power of 80%, and assuming a common standard devi-
ation of 1.3, a total of 48 evaluable patients per group
are to be included.
Populations of analysis
For safety analysis, all patients who have received at least
one dose of IVI will be considered, in the group of treat-
ment they actually received.
The intention to treat (ITT) population will consist of
all randomised patients with at least one Hb measure-
ment after POD 1. Patients with missing POD 30 assess-
ments (main endpoint) will be assigned the last value
available after POD1 (if any assessment is available). A
modified intention to treat population (mITT) will con-
sider all randomised patients with Hb assessments avail-
able at POD 30 irrespective of whether they have
adhered to the study protocol procedures.
The per-protocol (PP) population will consist of pa-
tients in the mITT populations who have received treat-
ment according to the study protocol and for whom an
80% adherence to oral iron is reported and with no rele-
vant protocol deviation that may affect main efficacy as-
sessments (i.e. transfusion).
Fig. 2 Schedule of enrolment, interventions and assessments
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Although the main efficacy analysis will be
performed on the PP population, the other two popu-
lations will be used for a sensitivity analysis for the
main endpoint.
Descriptive statistics
Patient characteristics will be described by treatment
group and for the entire sample of patients. Quantitative
variables will be presented as means with standard devi-
ations or in cases of skewed distribution as medians and
interquartile ranges. Qualitative data will be presented as
absolute and relative frequencies.
Inferential statistics
Differences in the main variable (change in Hb levels from
POD 1 to POD 30) between the treatment groups will be
tested by means of an analysis of covariance (ANCOVA)
using Hb at POD 1 as covariable. Chi-square test will be
used for the key secondary variable, percentage of patients
with Hb levels at POD 30 ≥ 13 g/dL, as well as for other
categorical variables. For categorical ordinal variables the
ANOVA or Kruskall–Wallis test will be used. Continuous
variables will be analysed by means of T-test or the corre-
sponding non-parametric tests. A subgroup analysis for
the stratification variable (Hb < 10 g/dL and Hb ≥ 10 g/dL)
is planned.
An exploratory multivariate analysis will be performed
to identify characteristics of patients associated to larger
changes in Hb levels and to identify subgroups of
patients that may benefit most of the single IVI dose.
Feasibility
Despite the large number of elective CRC surgeries per-
formed in our hospital (200 CRC surgeries are per-
formed each year on average), recruitment is limited by
the fact that only patients with Hb levels < 11 g/dL can
be included. Recruitment started in September 2015 and
is planned to finish in September 2018.
Ethics
Written informed consent will be obtained from each par-
ticipant before any trial-related procedures are carried
out. This trial is being conducted in accordance with the
Declaration of Helsinki and good clinical practice princi-
ples. The study protocol (Version 2, April 2015) was ap-
proved by the Research Ethics Committee of Corporació
Parc Taulí in April 2015 and by the Spanish Medicines
Agency (Agencia Española de Medicamentos y Productos
Sanitarios) in July 2015. The study is registered in the EU
Clinical Trials Register (EudraCT: 2015–001005-13). The
present study protocol has been written according to the
Recommendations for Interventional Trials (SPIRIT) 2013
statement for reporting a clinical trial protocol [15]. The
SPIRIT checklist is provided in Additional file 1.
Discussion
We have designed a randomised controlled study to
compare two IVI regimens to treat CRC postoperative
anaemia in terms of change in Hb levels from POD 1 to
POD 30. Other variables, such as percentage of patients
presenting with normal Hb levels at POD 30, changes in
iron metabolism parameters, safety of both IVI regimens
and complications and QoL, have been considered.
According to our procedures, patients with preopera-
tive anaemia follow an optimisation treatment with the
aim of reaching adequate levels before surgery and thus
minimising postoperative anaemia and the need for
transfusions. In addition, in our hospital, all patients
receive 200mg of iron sucrose right after surgery to
account for surgical blood loses. There are no clear rec-
ommendations on the use and efficacy of postoperative
iron treatment, especially in patients who have already
received IVI before surgery. In these cases, the risk of
iron overload has not been demonstrated. However,
there are a large number of patients who arrive at the
postoperative period with Hb levels lower than desired
[16, 17]. This may lead to complications, a longer hos-
pital stay and eventually to a slower recovery.
Currently, CRC patients without surgical complica-
tions are discharged after 3–4 days. This implies that, for
some patients, the treatment with fractionated IVI can-
not be completed to the calculated doses and thus they
are prescribed oral iron after discharge. However, the ab-
sorption of oral iron in this context is known to be min-
imal [1, 8–10, 12] and, together with the low compliance
expected due to mild but unpleasant side effects, pa-
tients end up receiving doses lower than required. To
overcome these problems, a single dose of 1000mg is an
option for patients with lower Hb levels. However, the
high cost of this formulation from a commercially avail-
able brand results in an underuse of this regimen in this
setting as evidenced in a previous study [14]. Thus, it is
of importance to assess whether, in patients with Hb
levels < 11 g/dL, treatment with single doses of IVI may
lead to larger increases in Hb levels and if this benefit
depends on POD 1 Hb levels or other characteristics of
patients, in order to make evidence-based decisions.
One of the main limitations of the study is the lack of
blinding. Masking of the different administration sched-
ules would need a double dummy strategy which would
modify the pragmatic approach of the study. Addition-
ally, the manufacturing of placebo and the masking pro-
cedures are a hurdle for an investigator-initiated study,
needing the logistic and economic support, in most
cases, of the marketing authorisation holder, a situation
which is not desirable for an independent trial. On the
other hand, the main endpoint is based on an analytical
parameter and thus it is less prone to be affected by ob-
servation bias.
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In addition, while we consider that studying the QoL
is a relevant endpoint, we foresee that changes in QoL
will be difficult to interpret due to the health condition
of patients before surgery.
In a previous observational study [14], we observed
that patients treated with postoperative IVI, increased
Hb levels in about 2 points at POD 30. Despite these in-
creases, a considerable number of patients do not reach
normal levels. Thus, we expect changes of this magni-
tude and expect them to be larger with the single dose
of ferric carboxymaltose than with the fractionated doses
regimen with iron sucrose. We also hypothesise that pa-
tients with lower Hb levels will benefit more from the
single-dose regimen.
The study is being performed in only one centre and,
in most cases, the principal investigator, an anaesthetist,
is responsible for the inclusion, randomisation and treat-
ment of the patient, ensuring uniformity of procedures.
Additionally, adapted risk monitoring has been imple-
mented to ensure that the protocol is performed accord-
ing to GCP criteria and to ensure the quality of data.
The results of this study will confirm whether the sin-
gle dose of 1000 mg of ferric carboxymaltose should be
preferred ahead of the fractionated doses and in which
type of patients this regimen should preferably be used.
Trial status
The trial is ongoing. At the time of finishing this manu-
script, 122 patients have been screened and signed in-
formed consent. Of those, 75 have been randomised
and 47 were not eligible, mainly due to Hb levels on
POD1 ≥ 11 g/dL.
Additional file
Additional file 1: SPIRIT 2013 Checklist: Recommended items to address
in a clinical trial protocol and related documents*. (DOC 122 kb)
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